LOADING
Comparing Johnson & Johnson (JNJ) and Merck & Company (MRK), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $651.3B | $376.4B |
| P/E Ratio | 31.4 | 122.0 |
| Forward P/E | 23.2 | 55.6 |
| PEG Ratio | 4.73 | 10.47 |
| EPS | $8.62 | $1.25 |
| Revenue Growth (YoY) | 6.6% | 5.1% |
| Profit Margin | 21.5% | 4.8% |
| Return on Equity | 25.7% | 7.0% |
| Dividend Yield | 1.96% | 2.23% |
| Beta | 0.23 | 0.21 |
| 52-Week High | $276.47 | $154.49 |
| 52-Week Low | $170.33 | $75.81 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.